New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 14, 2014
06:03 EDTBBBY, SHPGStocks with implied volatility below IV index mean; BBBY SHPG
Stocks with implied volatility below IV index mean; Bed Bath & Beyond (BBBY) 23, Shire (SHPG) 37 according to iVolatility.
News For BBBY;SHPG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
September 23, 2014
16:18 EDTBBBYBed Bath & Beyond sees Q4 EPS $1.78-$1.83
Subscribe for More Information
16:17 EDTBBBYBed Bath & Beyond sees FY14 EPS $5.00-$5.08, consensus $5.03
Subscribe for More Information
16:16 EDTBBBYBed Bath & Beyond sees Q3 EPS $1.17-$1.21, consensus $1.20
Subscribe for More Information
16:16 EDTBBBYBed Bath & Beyond reports Q2 EPS $1.17, consensus $1.14
Subscribe for More Information
15:27 EDTBBBYNotable companies reporting after market close
Notable companies reporting after the market close, with earnings consensus, include Bed Bath & Beyond (BBBY), consensus $1.14; Copart (CPRT), consensus 41c; HB Fuller (FUL), consensus 76c; Steelcase (SCS), consensus 23c; AAR Corp. (AIR), consensus 38c; Overland Storage (OVRL), one estimate (33c).
15:15 EDTBBBYBed Bath September weekly 63 straddle priced for 5.9% move into Q2
13:44 EDTSHPGISI Group to hold a webinar
Subscribe for More Information
12:51 EDTBBBYBed Bath & Beyond technical notes ahead of earnings
In the prior three months the shares have moderately outperformed the broader averages. The trend has been bullish, with very little volatility, over the interval. The stock is trading below the middle of its range for the last 52 weeks. There has been a strong degree of resistance at the $65 area since mid April of this year. On strongly bullish news, a breakout above $65 could turn the intermediate-term trend to bullish from neutral. Additional upside objectives could be at the following resistance levels on an increasing band of positive surprises: $67.25, $68.10, and $69.80. If the news is not bullish, the recent uptrend in the prior three months could be broken. A move that remains below $62 would break the short-term uptrend. Additional downside objectives could be at the following support levels on a progressive band of misses: $61.27, $59.61, and $57.80.
12:11 EDTSHPGOn The Fly: Midday Wrap
Stocks on Wall Street were mixed and little changed at midday, amid new rules from the Obama administration on tax inversions and manufacturing data from around the globe. ECONOMIC EVENTS: In the U.S., the FHFA's home price index rose 0.1% in July to 212.7, missing expectations for a rise of 0.5%. Markit's preliminary manufacturing Purchasing Managers' Index for September came in at 57.9, slightly below the consensus forecast for a 58.0 reading. The Richmond Fed manufacturing index for September rose to 14, beating expectations for it to have dropped two points to 10. In China, HSBC's flash manufacturing Purchasing Managers' Index rose to 50.5 from a final reading of 50.2 in August, better than expectations. In Europe, Markit's composite flash PMI for the eurozone dipped to a nine-month low of 52.3, missing expectations for it to hold steady at the 52.5 seen in August. COMPANY NEWS: Shares of several companies, including a number in the pharmaceutical industry, are lower in early trading after the Treasury Department announced new regulations yesterday night that aim to make it tougher for U.S. companies to lower their tax burdens via mergers with foreign companies, otherwise known as "inversions." Among the stocks that moved lower after the new rules were announced was Astrazeneca (AZN), which had previously been a target of Pfizer (PFE) and fell about 4% near midday. Also lower were shares of both Shire (SHPG), which fell 2%, and Abbvie (ABBV), which dropped 1.6%, as the two have previously agreed to merge in a tax inversion deal. Medtronic (MDT) and Covidien (COV), which similarly agreed to an inversion merger, were down 3.3% and 2.7%, respectively. MAJOR MOVERS: Among the notable gainers was Salix Pharmaceuticals (SLXP), which rose more than 5% after The Wall Street Journal reported that Allergan (AGN) is in advanced talks on a deal to buy the company. Shares of Allergan were also up nearly 3% near midday, as the Journal also reported that Allergan rejected a recent buyout offer from Actavis (ACT). Among the noteworthy losers was Ascena Retail (ASNA), which dropped 16% after the apparel retailer's fourth quarter results and fiscal 2015 profit outlook trailed analysts' consensus estimates. Also lower following its own earnings report was auto retailer CarMax (KMX), which fell over 9%. INDEXES: Near midday, the Dow was down 32.91, or 0.19%, to 17,139.77, the Nasdaq was up 2.90, or 0.06%, to 4,530.59, and the S&P 500 was down 2.29, or 0.11%, to 1,992.00.
10:54 EDTSHPGStocks, analysts react to Treasury inversion crackdown
Subscribe for More Information
10:02 EDTBBBYOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Analog Devices (ADI) downgraded to Neutral from Overweight at JPMorgan... Bed Bath & Beyond (BBBY) downgraded to Market Perform at William Blair... Cameco (CCJ) downgraded to Neutral from Buy at BofA/Merrill... Clorox (CLX) downgraded to Neutral from Buy at Citigroup... Concur (CNQR) downgraded to Neutral from Buy at Roth Capital... Del Frisco's (DFRG) downgraded at Sterne Agee... Dick's Sporting (DKS) downgraded to Market Perform from Outperform at William Blair... Dresser-Rand (DRC) downgraded to Hold from Buy at KeyBanc... Equinix (EQIX) downgraded to Market Perform from Outperform at Wells Fargo... Fluor (FLR) downgraded at Wells Fargo... Gordmans Stores (GMAN) downgraded at Canaccord... Jacobs Engineering (JEC) downgraded to Market Perform from Outperform at Wells Fargo... Nanometrics (NANO) downgraded to Hold from Buy at Canaccord... ON Semiconductor (ONNN) downgraded to Neutral from Overweight at JPMorgan... Siemens (SIEGY) downgraded to Equal Weight from Overweight at Barclays... Sigma-Aldrich (SIAL) downgraded to Hold from Buy at KeyBanc... Taminco (TAM) downgraded to Hold from Buy at Jefferies... Viasystems (VIAS) downgraded to Hold from Buy at Canaccord... Watsco (WSO) downgraded to Accumulate from Buy at Global Hunter.
09:20 EDTSHPGShire shares defended at CRT Capital
Subscribe for More Information
07:36 EDTBBBYBed Bath and Beyond weekly volatility elevated into Q2 and outlook
Subscribe for More Information
07:10 EDTBBBYBed Bath & Beyond downgraded to Market Perform at William Blair
Subscribe for More Information
05:46 EDTBBBYBed Bath & Beyond downgraded to Market Perform from Outperform at William Blair
Subscribe for More Information
September 22, 2014
07:31 EDTBBBYBed Bath & Beyond Q2 results likely similar to recent quarters, says UBS
UBS said it expects Bed Bath & Beyond's Q2 results to "look a lot like" its recent quarters, reflecting a modest comp sales increase and ongoing gross margin pressure. The firm maintains its Neutral rating and $62 price target on the stock.
September 19, 2014
11:06 EDTBBBYBed Bath and Beyond weekly volatility elevated into Q2 and outlook
Subscribe for More Information
September 18, 2014
10:40 EDTBBBYPier 1 Imports falls to 12-month low after weak Q2, lowered outlook
Shares of home furnishings retailer Pier 1 Imports (PIR) hit a 12-month low after the company's second quarter results fell below analysts' consensus estimates and it reduced its fiscal 2015 earnings per share outlook. WHAT'S NEW: Pier 1 Imports reported Q2 EPS of 10c on revenue of $418.6M, missing analysts' consensus estimates of 14c and $426.02M, respectively. Same-store-sales for the quarter were up 4.5%. The retailer lowered its FY15 EPS outlook to 95c-$1.05 from $1.14-$1.22. Analysts' consensus estimates for FY15 EPS prior to the earnings report was $1.13. The company sees FY15 SSS in the mid-to-high single digits and gross profit, as a percentage of sales, are expected to be 40.5%-41.5%. Pier 1 Imports CEO Alex Smith said that he foresees online sales to surpass $400M in 2016. WHAT'S NOTABLE: During the company's conference call, Pier 1 Imports said that it expects to see improving merchandise margins in coming quarters with fewer coupons. The company noted plans to continue returning cash to shareholders in the form of dividends and share buybacks. ANALYST REACTION: This morning, Wells Fargo analyst Matt Neemer downgraded Pier 1 Imports to Market Perform from Outperform. He feels that the stock will be a difficult one to own in the medium term as the retailer moves towards a multi-channel approach. Neemer believes that the company has a difficult journey ahead as it cuts broad-based discounters, and he feels that consumers will take time to get accustomed to the new messaging. He cut his price target range to $15-$16 from $19-$20 for the company. Barclays analyst Alan Rifkin downgraded Pier 1 Imports to Equal Weight from Overweight due to slow revenue growth and heightened promotions. He feels that that the "soft" revenues could continue. He believes that the company's elongated online profitability pipeline and increased promotions are certain to be a burden on the business in ways that the company had not initially thought. Rifkin said that growing the top line will be even harder in the absence of promotions. He reduced his price target for shares to $14 from $18. Argus analyst Christopher Graja downgraded Pier 1 Imports to Hold from Buy due to the company's lower than anticipated Q2 earnings. He feels that in terms of the home furnishings market, companies such as Williams-Sonoma (WSM), Home Depot (HD) and Lowe's (LOW) are more "resilient" for shareholders. Pier 1 Imports was also downgraded to Hold from Buy at BB&T. PRICE ACTION: In morning trading, Pier 1 Imports fell $2.63, or 16.99%, to $12.90. Including today's pull back, the stock is down approximately 45.2% over the past 12 months. OTHERS TO WATCH: Other companies in the home furnishings space include Restoration Hardware (RH), and Bed Bath & Beyond (BBBY).
September 17, 2014
09:50 EDTBBBYBed Bath & Beyond 2H guidance appears optimistic, says Cleveland Research
Cleveland Research checks indicate Bed Bath & Beyond Q2 sales trends remain flattish to up 1%, similar to Q1. The firm believes 2H guidance is too optimistic, especially for FY comps of +3%. The analyst remains cautious on shares and expect margin pressures to continue. Shares are Neutral rated.
07:43 EDTSHPGBofA/Merrill to hold a conference
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use